Wegovy Dosing Schedule: How Often Can You Take Wegovy for Effective Weight Management?

Last reviewed: June 30, 2026

Last updated: June 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, marketed as Wegovy for weight management, follows a structured once-weekly injection protocol designed to help your body adapt gradually to the medication. Most patients begin at a 0.25 mg dose and increase by 0.25 mg increments every four weeks, reaching maintenance doses between 1.7 mg and 2.4 mg. The frequency and dose customization depend on your individual tolerance, metabolic response, and clinical goals.

Weekly Semaglutide Injection Protocol: Standard Dosing Schedule

Semaglutide for weight management uses a once-weekly subcutaneous injection regimen, meaning you inject the medication under your skin one time each week on the same day. This consistent weekly timing allows your body to maintain steady hormone levels throughout the seven-day cycle, supporting appetite regulation and metabolic changes. The medication reaches peak concentration within 24 to 48 hours after injection, then gradually decreases over the week—which is why spacing injections exactly seven days apart maintains therapeutic benefit.

The standard titration protocol spans 16 weeks and begins at 0.25 mg per week, increasing by 0.25 mg increments every four weeks. This gradual escalation gives your gastrointestinal system time to adjust and helps minimize nausea and other early-phase side effects. Most clinical trial participants reached maintenance doses of 1.7 mg or 2.4 mg weekly by week 16, though some individuals respond well to lower maintenance doses of 1.0 mg or 1.2 mg.

Personalized Dosing Titration: When to Increase Your Injection

Your healthcare provider decides when to advance your semaglutide dose based on your tolerance, gastrointestinal symptoms, and weight loss progress rather than on a fixed calendar schedule. If you experience significant nausea, vomiting, or stomach discomfort during a four-week interval, your provider may delay the dose increase by one to two weeks to allow adaptation. Conversely, if you tolerate the current dose very well and hunger suppression wanes, moving to the next dose level earlier may improve appetite control and weight loss momentum.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Wegovy or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Maintenance Dose vs. Titration Phase: What to Expect

The titration phase lasts 16 weeks and includes five dose increases, starting at 0.25 mg and advancing by 0.25 mg weekly increases every four weeks until reaching a target maintenance dose. During titration, your appetite and food preferences shift gradually; most patients report noticeably reduced hunger, increased fullness from smaller meals, and diminished cravings for high-calorie foods. Weight loss typically accelerates during weeks 8 through 16 as you reach higher therapeutic doses.

Once you reach your maintenance dose—usually 1.7 mg, 2.0 mg, or 2.4 mg weekly—you continue injecting that same amount every seven days indefinitely or for as long as your provider recommends continued therapy. Maintenance is not an increase phase; you remain on the same dose week after week to sustain appetite suppression and metabolic benefits. Some patients maintain weight loss at 1.0 mg or 1.2 mg, while others require 2.4 mg for optimal control, reflecting biological variation in GLP-1 receptor density and sensitivity.

PlexusDx Compounded Semaglutide: Consistent Dosing at One Flat Price

PlexusDx provides compounded semaglutide injections from licensed 503A compounding pharmacies, ensuring pharmaceutical-grade purity and potency regardless of which dose level you use. Unlike brand-name Wegovy, which may have supply constraints or insurance coverage gaps, PlexusDx compounded semaglutide serves all 50 states without requiring insurance, membership fees, or employer sponsorship. Your monthly cost remains flat at $189 across all dose levels—meaning your dose may increase during titration, but your price stays the same.

Patients interested in exploring whether oral semaglutide might suit their lifestyle can also access PlexusDx Oral Semaglutide, at $289/mo month-to-month, or from $249/mo on the 6-month plan. PlexusDx also offers tirzepatide (a dual GLP-1/GIP receptor agonist) as an injection or oral option, plus the proprietary GLP-Squared dual-compound injection combining semaglutide and tirzepatide for patients seeking synergistic effects. All products are HSA and FSA eligible, expanding affordability for eligible account holders.

How Genetic Factors Shape Your Optimal Injection Schedule

Genetic variations in the GLP-1 receptor gene GIPR receptor gene (GIPR rs1800437), and metabolic pathways like FTO and MC4R influence how your body responds to weekly semaglutide injections. Some individuals carry genetic patterns associated with higher GLP-1 receptor expression, potentially allowing them to respond effectively at lower doses, while others have variants linked to lower receptor density or altered peptide signaling. These differences partly explain why one patient thrives on 1.0 mg weekly while another requires 2.4 mg for comparable appetite suppression.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

How often do you inject Wegovy or semaglutide for weight loss?

Semaglutide is injected once per week, every seven days, on the same day each week. You start at 0.25 mg and increase by 0.25 mg every four weeks during the 16-week titration phase, reaching a maintenance dose of 1.0 mg to 2.4 mg weekly depending on your individual tolerance and response.

Can you take Wegovy more than once a week?

No, semaglutide for weight management is designed and approved for once-weekly injection only. Taking it more frequently increases the risk of overdose, severe gastrointestinal side effects, and potential toxicity. The once-weekly schedule optimizes the balance between appetite suppression and medication tolerance.

What if I miss a weekly semaglutide injection?

If you miss your weekly injection by one to two days, take it as soon as you remember, then resume your regular weekly schedule from that new date. If you miss a dose by more than a few days, skip that missed dose and inject on your regular scheduled day the following week—do not double up on doses.

How much weight can you lose with weekly semaglutide injections?

Clinical trials show that patients on semaglutide 2.4 mg weekly lose an average of 15% to 18% of their starting body weight over 68 weeks, compared to 2% to 3% with placebo. Individual results vary based on genetics, diet, exercise, and how consistently you advance through the titration schedule.

Does PlexusDx charge more if my semaglutide dose increases?

No. PlexusDx compounded semaglutide costs $189 per month flat across all dose levels—your dose may go up during titration, but your price does not. This pricing model removes barriers to advancing your therapy to the dose that works best for your body.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy For Losing Weight
• Wegovy For Weight Loss 2
• Wegovy Providers That Take Fsa Plexusdx
• Tirzepatide Dosing Schedule Plexusdx

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.